GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Clinical trials for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE trials appear
Sign up with your email to follow new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Laser zaps brain tumor, then immunotherapy fights back: new hope for glioblastoma?
Disease control Not yet recruitingThis study tests a new approach for recurrent glioblastoma, an aggressive brain cancer. It combines a minimally invasive laser that heats and destroys tumor tissue (LiTT) with an immunotherapy drug called cemiplimab, which helps the immune system attack cancer cells. About 99 par…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Experimental brain cancer therapy targets tumors directly
Disease control Not yet recruitingThis study tests a new treatment called MT027 for people with recurrent glioblastoma, an aggressive brain cancer. MT027 uses specially engineered immune cells (UCAR-T cells) that are injected directly into the fluid around the brain. The trial will include 40 adults aged 18-70 an…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE2 • Sponsor: T-MAXIMUM Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC